Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a leading medical products company specializing in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration. The company's core mission is to restore peripheral nerve function and improve the quality of life for patients suffering from traumatic injuries or surgical procedures that impact nerve function and sensation.
Axogen's innovative product portfolio includes:
- Avance® Nerve Graft: The first and only commercially available allograft for bridging nerve discontinuities.
- Axoguard® Nerve Connector: A coaptation aid designed for the close approximation of severed nerves.
- Axoguard® Nerve Protector: A product that shields nerves during the healing process.
- Axoguard® Nerve Cap: A surgical implant to isolate and protect a peripheral nerve end, minimizing painful neuroma development.
- Axoguard HA+ Nerve Protector: A next-gen nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries.
- Avive® Soft Tissue Membrane: A biologically active product aiding in nerve healing.
- Axotouch® Two-Point Discriminator: An assessment tool for measuring the innervation density of skin surface areas.
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. The company continues to expand its global presence and partnerships, ensuring that healthcare providers and surgeons have access to clinically and economically effective nerve repair solutions.
Recent achievements include the launch of the Axoguard HA+ Nerve Protector, which provides enhanced nerve gliding and protection for a wide range of peripheral nerve injuries. The company reported strong performance in Q4 2023, with an expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
For more information, visit www.axogeninc.com.
Axogen Inc (NASDAQ: AXGN), a global leader in surgical solutions for peripheral nerve injuries, has scheduled its 2024 fourth quarter and full year financial results announcement for Tuesday, February 25, 2025, before market opening. The company will host an investment-community conference call and webcast at 8 a.m. ET on the same day.
Investors can participate in the conference call by dialing (877) 407-0993 (toll-free) or (201) 689-8795 (direct). The webcast will be accessible through the Investors page on Axogen's website, where a replay will also be available after the call.
Axogen (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, has appointed Jesse Bishop as Vice President of Regulatory Affairs. Reporting to CEO Michael Dale, Bishop will lead domestic and international regulatory strategies for new product development, market approval, and regulatory initiatives.
Bishop brings over 13 years of leadership experience in regulatory strategy and CMC, CGMP manufacture of cell and gene therapies, having worked at companies including Thermo Fisher Scientific, RGI Medical Manufacturing, and Ology Bioservices. He served in the U.S. Army Special Operations as a Ranger Team Leader and Combat Medic and holds master's degrees in medical sciences and business administration from the University of Florida.
As part of his employment package starting February 3, 2025, Bishop will receive an inducement grant of 45,000 Restricted Stock Units (RSUs) on March 3, 2025. The RSUs will vest over 4 years, with 50% vesting after two years and 25% vesting annually for the following two years.
Axogen (NASDAQ: AXGN) has appointed Craig Swandal as Vice President of Operations, reporting to CEO Michael Dale. Swandal brings over 25 years of experience in medical device manufacturing leadership, including roles at Tendyne, Meier Tool and Engineering, ATS Medical, and Gyrus Medical.
As VP of Operations, Swandal will oversee manufacturing, supply chain, infrastructure strategies, tissue processing, distribution, purchasing, planning, manufacturing and process engineering, customer care, and continuous improvement.
As an inducement for employment, Swandal will receive an equity grant comprising 58,000 Restricted Stock Units (RSUs) vesting over 4 years and 58,000 Performance Stock Units (PSUs) tied to company stock price goals between February 2024 and February 2027. The PSUs can range from 0% to 200% based on achievement of specific stock price targets.
Axogen (NASDAQ: AXGN) announced preliminary unaudited revenue figures for Q4 and the full year 2024. The company expects fourth-quarter revenue of approximately $49.4 million, a 15.1% increase from Q4 2023. Full-year revenue is anticipated to be around $187.3 million, a 17.8% increase over 2023. This growth is attributed to improved execution of commercial strategies and increased adoption of Axogen's surgical solutions, particularly in Extremities and OMF-Head & Neck applications, as well as Resensation® for post-mastectomy breast reconstruction. Axogen projects a full-year gross margin above 75.5% and expects its cash, cash equivalents, and investments to total around $39.5 million by year-end, up $2.5 million from 2023. CEO Michael Dale expressed satisfaction with the company's performance and announced an Investor Day on March 4th, 2025, to share future strategic priorities. The results are preliminary and unaudited, with full audited results expected to be reported on or before Investor Day.
Axogen (NASDAQ: AXGN) reported Q3 2024 financial results with revenue of $48.6 million, up 17.9% year-over-year. Gross margin decreased to 74.9% from 76.8% in Q3 2023. Net loss improved to $1.9 million ($0.04 per share) compared to $4.1 million ($0.10 per share) last year. Adjusted EBITDA reached $6.5 million, up from $2.4 million in Q3 2023.
The FDA accepted the company's Biologics License Application for Avance Nerve Graft with a PDUFA date of September 5th, 2025. Axogen maintains full-year revenue guidance of $182-186 million and expects to be at the high end of its 74-76% gross margin range.
Axogen (NASDAQ: AXGN), a global leader in surgical solutions for peripheral nerve injuries, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, before market opening. The company will host an investment-community conference call and webcast at 8 a.m. ET on the same day. Investors can participate via phone by dialing (877) 407-0993 (toll-free) or (201) 689-8795, or listen online through the Investors page at www.axogeninc.com. A replay will be available on the company's website after the call.
Axogen (NASDAQ: AXGN) has completed the rolling submission process for its Biologics License Application (BLA) to the FDA for Avance Nerve Graft®. This marks a significant step in transitioning Avance from a tissue to a biologic. The company expects FDA notification on submission acceptance and review timeline within 60 days. Avance Nerve Graft has previously received Regenerative Medicine Advanced Therapy (RMAT) designation, potentially streamlining the development process. Axogen has requested priority review status, which could reduce the review timeline from 10 months to 6 months. The company anticipates an FDA determination of approvability between April and September of next year.
Axogen (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, has granted an equity inducement award to a new non-executive employee on September 3, 2024. The award, approved by the Compensation Committee of Axogen's Board of Directors, complies with NASDAQ Listing Rule 5635(c)(4) and serves as a material inducement for the employee's acceptance of employment.
The award consists of restricted stock units (RSUs) representing 10,000 shares of Axogen's common stock. The RSUs have a 4-year vesting schedule: 50% vesting after two years, followed by 25% vesting annually for the next two years.
Axogen (NASDAQ: AXGN) announces significant leadership changes effective August 9, 2024. Michael Dale is appointed as the new CEO and Director, succeeding Karen Zaderej, who will remain in an advisory role for nine months. Paul Thomas, a current board member, will become the new Chairman of the Board.
Dale brings over 30 years of experience in leading medical technology companies. The company aims to focus on commercial expansion, broad-based revenue growth, and driving toward sustainable positive cash flow and profitability. As part of his employment agreement, Dale was granted 600,000 performance stock units, with vesting tied to stock price goals and the approval of Axogen's biologics license application for Avance Nerve Graft®.
Axogen, Inc. (NASDAQ: AXGN) reported strong financial results for Q2 2024. Revenue increased by 25.6% to $47.9 million compared to Q2 2023. The company's net loss narrowed to $1.9 million ($0.04 per share), down from $6.7 million in Q2 2023. Adjusted net income was $2.0 million ($0.05 per share), and adjusted EBITDA reached $5.6 million.
Axogen's gross margin decreased to 73.8% from 77.7% in Q2 2023. The company's cash position improved to $27.1 million. Core Accounts grew by 18.7% year-over-year to 412. Axogen initiated the rolling submission process for its Biologics License Application for Avance Nerve Graft® and expects to complete it in Q3 2024.
The company increased its 2024 revenue guidance to $182-$186 million and adjusted gross margin guidance to 74-76%. Axogen anticipates being net cash flow positive from April 1st through year-end.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
What is Axogen, Inc. focused on?
What are some key products offered by Axogen?
In which markets are Axogen's products available?
What recent product did Axogen launch?
What is the Avance® Nerve Graft?
How did Axogen perform financially in Q4 2023?
What does the Axoguard® Nerve Cap do?
What is the function of the Axotouch® Two-Point Discriminator?
Who is the current CEO of Axogen?
Where can I find more information about Axogen?
